Excellence is just the beginning.


French German Italian Portuguese Russian

News Releases

January 17, 2019
Researchers at Rush University Medical Center and the MIND Institute at UC Davis have found that mavoglurant, an experimental drug known as an mGluR5 negative modulator, can positively modify a key characteristic behavior in individuals with fragile X syndrome.